DAFTAR PUSTAKA
American Cancer Society (2010): Breast Cancer Facts and Figures 2009-2010. http://www.cancer.org/acs/groups/content/@nho/documents/document
/f861009final90809pdf.pdf
Antoine, C., Leibens, F., Carly, B., Pastijn, A. and Rozenberg, S. (2004): Influence of HRT on prognostic factors for breast cancer: a systematic review after thewomen's health initiative trial. Hum. Reprod., 19: 741-56.
Armstrong, K., Eisen, A., and Weber, B. (2000): Assessing the risk of breast cancer. New Engl. J. Med., 342:564-71.
Autier, P. (2002):A breast cancer screening program operating in a liberal health care system: the Luxembourg Mammography Program, 1992-1997. Int. J. Cancer, 97: 828-32.
Axilbund, J.E., Gross, A.L., Visvanathan, K. ( 2011): Chapter 5 in Early diagnosis and treatment of cancer Series: Breast Cancer. Jacobs L. and Finlayson C.A (Ed) Saunders Elsevier: pp 71-88.
Backus, J., Laughlin, T., Wang, Y., Belly, R., Robert, W., Baden, J., Min, C. J., Mannie, A., Tafra, L., Atkins, D. and Verbanac, K.M. (2005): Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. Journal of MolecularDiagnostics, 7:327–336.
Bae J.W., Choi K.H., Kim H.G., Park S.H. (2000): The detection of circulating breast cancer cells in peripheral blood by Reverse Transcriptase-Polymerase Chain Reaction. J. Korean Med Sci, 15: 194-8.
Bernstein J.L., Godbold J.H., Raptis G., Watson M.A., Levinson B., Aaronson S.A., Fleming T.P.(2005): Identification of Mammaglobin as a Novel Serum Marker for Breast Cancer. Clin Cancer Res, 11:6528-6535
Bitisik, O., Saip, P., Saglam, S., Derin, D. And Dalay, N. (2009): Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genetics and Molecular Research 9(1): 97-106
BRCA 1/2 gene mutation carriers and women with high familial risk. J. Clin. Oncol., 19: 924-30.
Canda, M.S., Gury, M., Erbayraktar, R.S., Acar, F. and Canda, T. (2004):
Association of invasive breast Carcinoma and Glioblastoma multiforme: a case report with histological and immunohistochemical features. Turk. J. Med. Sci., 34: 131-135.
Carter, D., Dillon, D.C., Reynolds, L.D., Retter, M.W., Fanger , G., Molesh, D.A., Sleath, P.R., McNeill, P.D., Vedvick, T.S., Reed, S.G., Persing, D.H. and Houghton, R.L.( 2003):Serum antibodies to lipophilin-B detected inlate stage breast cancer patients. Clin. Cancer Res., 9:749-754.
Cerveira, N., Torres, L., Rocha, P., Bizarro, S., Pereira, D., Abreu, J., Teixeira, M.R. and Castedo, S. (2004): Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancerpatients. Int. J. Cancer, 108: 592–595.
Collado, M., Landt, O., Barragán, E., Lass, U., Cervera, J., Sanz, M. A. And Bolufer, P. (2004): Locked nucleic acid-enhanced detection of 1100delC*CHEK2 germ-linemutation in Spanish patients with hematologic malignancies. Clin. Chem., 50: 2201 - 2204.
Connor, E. and Stuenkel, C.A. (2001):Hormone replacement therapy (HRT)-risks and benefits. Int. J. Epidemiol., 30: 423-6.
Corradini, P., Voena, C., Astolfi, M., Dell´Oro, S., Pilotti, S., Arrigoni, G., Bregni, M., Pileri, A. and Gianni, A.M. (2001): Maspin and mammaglobin genes arespecific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann. Oncol., 12:1693–1698.
Cristofanilli, M., Hayes, D.F., Budd, G. T., Ellis, M.J., Stopeck, A., Reuben, J.M., Doyle, G.V., Matera, J., Allard, W.J., Miller, M. C., Fritsche, H.A., Hortobagyi, G.N. and Terstappen, L.W.M.M. (2005): Circulating Tumor Cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology, 23(7): 1420-1430.
De la Hoya, M., Gutiérrez-Enríquez, S., Velasco, E., Osorio, A., de Abajo, A.S., Vega, A., Salazar, R., Esteban, E., Llort, G., Gonzalez-Sarmiento, R., Carracedo, A., Benítez, J., Miner, C., Díez, O., Díaz-Rubio, E. and Caldes, T. (2006): Genomic Rearrangementsat the BRCA1 Locus in Spanish families with breastovarian cancer.
Clin. Chem., 52: 1480-1485
Duffy, M.J. (2005):Predictive markers in breast and other cancers. Clin. Chem., 51: 494–503.
Duffy, M.J. (2006): Serum tumor markers in breast cancer: Are they of clinical value? Clin. Chem., 52: 345-51.
Elahi, M., Norat, T., Goudable, J. and Riboli, E. (2004):Biomarkers of dietary fat intake and the risk of breastcancer: A meta-analysis. Int. J. Cancer, 111: 584-91.
Elmore, J.G., Miglioretti, D.L. and Carney, P.A. (2005): Does practice make perfect when interpretingmammography? part II. J. Natl. Cancer Inst., 95:250-2.
El-Sharkawy S.L., El-Aal W.S.A., El-Shaer M.A.M., Abbas N.F., Youssef, M.F.(2007):Mammaglobin: A novel tumor marker for breast cancer,Turkish Journal of Cancer 37 (3) : 89-97.
Ergul E. and Sazci A.(2001): Molecular Genetics of Breast Cancer. Turk J Med Sci 31: 1-14
Frazier, A.L., Ryan, C.T., Rockett, H., Willett, W.C. and Colditz, G.A. (2003):
Adolescent diet and risk of breastcancer. Breast Cancer Res., 5: R59-R64.
Gasco, M., Shami, S. and Crook, T. (2002): The p53 pathway in breast cancer.
Breast Cancer Res., 4: 70-76.
Giard, R.W.M. and Hermans, J. (1992): The value of aspiration cytology of the breast. Cancer, 69: 2104-2110.
Gillanders, W.E. (2005): Clinical translation of a Mammaglobin-A DNA vaccine for Breast Cancer Therapy. Ph.D. Thesis, Washington University School of Medicine.
Giordano, S.H. (2005):A review of the diagnosis and management of male breast cancer. Oncologist, 10: 471-9.
(Fred) and Dorssers, L.C.J. (2004): Development of an ELISA for measurement of BCAR1 protein in humanbreast cancer tissue . Clinical Chemistry, 50:1356-1363.
Grünewald, K., Haun, M., Urbanek ,M., Fliegl, M., Mueller-Holzner, E., Gunsilius, E., Dünser, M., Marth, C. and Gastl, G. (2000): Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor and cytokeratin-19. Lab. Invest., 80: 1071– 1077.
Guadagni, F., Ferroni, P., Carlini, S., Mariotti, S., Spila, A., Aloe, S., D´Alessandro, R., Carone, M.D., Cicchetti, A., Riccoiotti, A., Venturo, I., Perri, P., Filippo, F. D., Cognetti, F., Botti, C. and Roselli, M. (2001): A reevaluation of carcinoembryonic antigen (CEA) as a serummarker for breast cancer. Clin. Cancer Res., 7: 1257- 2362.
Harbeck, N., Kates, R.E., Look, M.P., Gelder, M.M., Klijn, J.G.M. and Kruger, A. (2002): Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activatorinhibitor type 1 (N = 3424). Cancer Res., 62: 4617–4622.
Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.F.,and Bast Jr R.C.(2007): American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Marker in Breast Cancer. J. of Clin. Onc. 25(33): 5287-5312.
Hellström, L., Goodman, G., Pullman, J., Yang, Y. and Hellström, K. E. (2001): Overepreesion oh HER-2in ovarian carcinoma. Cancer Research, 61: 2420-2423
Henry, N.L. and Hayes, D.F. (2006):Uses and abuses of tumor markers in the diagnosis monitoring and treatment of primary and metastatic breast cancer. Oncologist, 11(6)541-52.
Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J. And Thun, M. J. (2007):
Cancer statistics, 2007. CA Cancer J.Clin., 57:43-66.
Jones G. (1999): CA 15-3. SydPath. gjones@stvincents.com.au
Koga, T., Horio, Y., Mitsudomi, T., Takahashi, T. and Yatabe, Y. (2004):
Lacroix M.(2006): Significance, detection and markers disseminated breast cancer cells. Endocrine-Related Cancer, 13: 1033–1067.
Lee I.M., Cook N.R., Rexrode K.M. and Buring J.E. (2001): Lifetime physical activity and risk of breast cancer. British Journal of Cancer., 85(7), 962–965
Loman, N., Bladström, A. Johannsson, O., Borg, A. And Olsson, H. (2003):
Cancer incidence in relatives of a population- based set of cases of early- onset breast cancerwith a known BRCA1 and BRCA2 mutation status. Breast Cancer Res., 5: R175- R186.
Margolese R.G., Fisher B., Hortobagyi G.N. and Bloomer W.D.(2003): Chapter 118 Neoplasms of the Breast: Cancer Medicine, 6th Edition"
McTieranan, A., Rajan, K.B., Tworoger, S.S., Irwin, M., Bernstein, L., Baumgartner, R., Gilliland, F., Stanczyk, F.Z., Yasui, Y. and Ballard-Barbash, R. (2003): Adiposity and sex hormones in postmenopausal breast cancer survivors.
Journal of Clinical Oncology, 21: 1961-6.
Mikhitarian, K., Martin, R.H., Ruppel, M. B., W.E. Gillanders, W.E., Hoda, R., Schutte, D.H., Callahan, K., Mitas, M. and Cole, D.J. (2008): Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospectivecohort study. BMC. Cancer, 8:55.
Miksicek, R.J., Myal, Y., Watson, P.H., Walker, C., Murpohy,L.C. and Leygue, E. (2002): Identification of a novel breast-and salivary gland-specific, Mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res., 62: 2736-2740.
Molina, R., Barak, V., van Dalen, A., Duffy, M.J., Einarsson, R. and Gion, M. (2005):Tumor markers inbreast cancer: European Group of TumorMarkers (EGTM)recommendations. Tumor Biol., 26: 281–293.
Notani, P.N.(2001): Global variation in cancer incidence and mortality. Current science, Vol. 81, No. 5
Oakley, K.L., Going, J.J. (1995): Specimen slice radiography of cancer in breast conserving excisions. J.Clin. Pathol 48:1028-30
O'Brien, N., Maguire, T.M., O'Donovan, N., Lynch, N., Hill, A. D.K., McDermott,
E., O’Higgins, N. and Duffy, M.J.(2002): Mammaglobin A: a promising marker for breast cancer.Clin. Chem., 48(8): 1362-1364.
Passebosc-Faure, K., Li, G., Lambert, C., Cottier, M., Gentil-Perret, A., Fournel, P.; Pérol, M. and Genin, C. (2005): Evaluation of a panel of molecular markers for thediagnosis of malignant serous effusions. Clin. Cancer Res.,11(19).
Perkins G.L., Slater E.D., Sanders G.K., Prichard J.G.(2007): Serum Tumor Markers. American Family Physician, 68 (6): 1075-82.
Peto, J. (2002):Breast cnacer susceptibility: A new look at an old model.,Cancer Cell, 1: 411-2.
Poschl, G. and Seitz, H.K. (2004):Alcohol and cancer. Alcohol, 39: 155-65.
Raina, V., Bhutani, M., Bedi, R., Sharma, A., Deo, S.V., Shukla, N.K., Mohanti, B.K. and Rat, G.K. (2005): Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J.Cancer, 42: 40-5.
Raynor, M., Stephenson, S.A., Walsh, D.C.A., Pittman, K.B. and Dobrovic, A. (2002): Optimization of the RTPCR detection of immunomagnetically enriched carcinomacells. Cancer, 2:14-21.
Roncella, S., Ferro, P., Bacigalupo, B., Pronzato, P., Tognoni, A., Falco, E., et al (2005): Human mammoglobin m-RNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. J. Exp. Clin. Cancer Res., 24.2
Roncella, S., Ferro, P., Bacigalupo,B., Dessanti, P., Giannico A., Gorji, N., et al (2006): Relationship between Human Mammaglobin mRNA Expression in Breast Cancer Tissue and Clinico-Pathology features of the Tumor. J. Exp. Clin. Cancer Res., 25.1
Silva, A.L., Tome, M.J., Correia, A.E., and Passos-Coelho, J.L. (2002): Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoieticproducts. Ann. Oncol., 13: 442–429.
Singletary, S.E., Greene, F.L., Sobin, L.H. (2003): Classification of Isolated Tumor Cells Clarification of the 6th Edition of the American Joint on Cancer Staging Manual. American Cancer Society.
Singletary, S. E. and Connolly, J.L. (2006): Breast Cancer Staging: Working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J. Clin., 56:37-47.
Sjödin, A. (2005): Human Secretoglobins in Normal and Neoplastic Cells and Tissues. Medical dissertation, University of Umeå, Sweden.
Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V. and Bajamonde, A. (2001): Use of chemotherapy plus a monoclonal antibody against HER- 2 for metastatic breast cancer that overexpress HER-2.N. Engl. J. Med., 344:783–92.
Smigal, C., Jemal, A., Ward, E., Cokkinides, V., Smith, R., Howe, H. L. And Thun, M. (2006): Trends in breast cancer by race and ethnicity: Update 2006. CA Cancer J.Clin., 56:168-183.
Span, P.N., Waanders, E., Manders, P., Heuvel, J., Foekens, J.A., Waston, M.A. and Sweep, F. (2004):Mammaglobin is associated with low-grade, steroid
receptor-positive breast tumors from postmenopausal patients, and has independent
prognostic value for relapse freesurvival time. J. Clin. Oncol., 22(4): 691-698.
Stewart, S.L., King, J.B., Thompson, T.D., Friedman, C and Wingo, P.A. (2004) :
Cancer mortality surveillance United States, 1990-2000. Morbidity and mortality WeeklyReport, 53: 1-108.
Terry, P.D. and Rohan, T.E. (2002): Cigarette smoking and the risk of breast cancer in women. Cancer Epidem., 11: 953-971.
Tjindarbumi D and Mangunkusumo R.(2002): Cancer in Indonesia, Present and Future. Jpn J. Clin. Oncol; 32(Supplement 1)S17-S21
Ursin, G., Bernstein, L., Lord, S., Karim, J.R., Deapen, D., Press, M.F., Daling, J.R., Norman, S.A., Liff, J.M. and Marchbanks, P.A. (2005): Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br. J. Cancer, 93: 364-71.
Watson, M.A. and Fleming, T.P. (1996): Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer.
Cancer Res., 56(4): 860-865.
Watson, M.A., Darrow, C., Zimonjic, D.B., Popescu, N.C. and Fleming, T.P. (1998):Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. Oncogene, 16(6): 817-824.
Watson, M.A., Dintzis, S., Darrow, C.M., Voss, L.E., Pipersio, J., Jensen, R. and Fleming, T.P. (1999): Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res., 59(13): 3028-3031.
Winchester D.P. (1992): Physical Examination of the Breast. Cancer Supplement, Volume 69, No. 7
Wood, W.C., Muss, H.B., Solin, L.J., Olopade, O.I. (2005): Malignant Tumors of the breast Cancer. In: Principles and Practice of Oncology.7th Ed, V.T. DeVita, S. Hellman, S.A. Rosenberg(Eds). Philadelphia, Lippincott Williams & Wilkins, pp: 1415-77
Woodward, W.A., Strom, E.A., Tucker, S.L., McNeese, M.D., Perkins, G.H., Schechter, N.R., Singletary, S.E., Theriault, R.L., Hortobagyi, G.N., Hunt, K.K. and Thomas A. Buchholz (2003): Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific Survival.
Journal of Clinical Oncology, 21 (17): 3244-3248
Wrensch, M.,Chew, T., Farren, G., Barlow, J., Belli, F., Clarke, C., Erdmann, C.A., Lee, M., Moghadassi, M., Peskin-Mentzer, R., Quesenberry Jr, C.P., Souders-Mason, V., Spence, L., Suzuki, M. and Gould, M. (2003): Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Research, 5 (4)
Zehentner, B. K., Persing, D. H., Deme, A., Toure, P., Hawes, S. E., Brooks, L., Feng, Q., Hayes, D. C., Critichlow, C. W., Houghton, R. L.and Kiviatet, N. B. (2004): Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISA. Clinical Chemistry, 2069–2076.
Zhang, S.M., Manson, J.E., Rexrode, K.M., Cook, N.R., Buring, J.E. and Lee, I.M. (2007): Use of oral conjugated estrogen alone and risk of breast cancer. Am. J.
